(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 4.58% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.69%.
Amneal Pharmaceuticals's revenue in 2024 is $2,495,258,000.On average, 3 Wall Street analysts forecast AMRX's revenue for 2024 to be $812,616,100,229, with the lowest AMRX revenue forecast at $803,382,485,754, and the highest AMRX revenue forecast at $817,620,573,591. On average, 3 Wall Street analysts forecast AMRX's revenue for 2025 to be $845,255,056,970, with the lowest AMRX revenue forecast at $832,494,483,256, and the highest AMRX revenue forecast at $861,168,195,807.
In 2026, AMRX is forecast to generate $881,742,896,331 in revenue, with the lowest revenue forecast at $854,995,168,347 and the highest revenue forecast at $908,490,624,316.